Evolution of allograft fibrosis and function in kidney transplant recipients: a retrospective analysis of stable patients under CNI and mTORi
- 16 February 2015
- journal article
- Published by Frontiers Media SA in Transplant International
- Vol. 28 (5) , 553-564
Abstract
Histological evaluations of renal allograft biopsies are essential for diagnosis, but still show a low predictive value for long-term allograft function. One limitation relies on the fact that the analysis is usually based on a single biopsy sample, and therefore, no dynamic changes are considered. Using two distinct approaches, we evaluated the evolution of fibrosis and related markers in 36 stable kidney transplant patients under calcineurin inhibitor therapy with two indication biopsies each, prior and at least 6 months after substitution by mTORi (N = 18), or maintenance on CNI (N = 18). In the method comparison, both Banff chronicity score and the digitally assessed fibrosis were correlated with allograft function at biopsy (r = -0.36 and r = -0.72, P = 0.002 and P < 0.0001, respectively). However, only the progression of fibrosis digitally assessed was correlated with allograft function loss, not only within the time between biopsies (r = -0.47, P = 0.004) but also in the 60-month follow-up (r = -0.47, P = 0.006). In the group analysis, despite of a higher incidence of C4d positivity (P = 0.05), progression of fibrosis, TGF-β1 expression, and allograft function decline were significantly lower after conversion to mTORi compared with maintenance on CNI (P = 0.05, P = 0.02 and P = 0.01, respectively). PDGF, VEGF, b-FGF, and HIF1A expressions remained stable over time regardless of therapy.Keywords
This publication has 51 references indexed in Scilit:
- Incidence of donor‐specific antibodies in kidney transplant patients following conversion to an everolimus‐based calcineurin inhibitor‐free regimenClinical Transplantation, 2013
- Rapamycin Ameliorates Kidney Fibrosis by Inhibiting the Activation of mTOR Signaling in Interstitial Macrophages and MyofibroblastsPLOS ONE, 2012
- Delayed mTOR Inhibition with Low Dose of Everolimus Reduces TGFβ Expression, Attenuates Proteinuria and Renal Damage in the Renal Mass Reduction ModelPLOS ONE, 2012
- Efficacy and Safety of Early Cyclosporine Conversion to Sirolimus with Continued MMF—Four-Year Results of the Postconcept StudyAmerican Journal of Transplantation, 2011
- The Histology of Solitary Renal Allografts at 1 and 5 Years After TransplantationAmerican Journal of Transplantation, 2011
- Morphometric and Visual Evaluation of Fibrosis in Renal BiopsiesJournal of the American Society of Nephrology, 2011
- mTOR inhibition: the learning curve in kidney transplantationTransplant International, 2010
- Noncanonical TGF-β pathways, mTORC1 and Abl, in renal interstitial fibrogenesisAmerican Journal of Physiology-Renal Physiology, 2010
- Conversion From Calcineurin Inhibitors to Sirolimus Maintenance Therapy in Renal Allograft Recipients: 24-Month Efficacy and Safety Results From the CONVERT TrialTransplantation, 2009
- The Banff 97 working classification of renal allograft pathologyKidney International, 1999